SPARC

Across TCGA pan-cancer cohorts, SPARC mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SPARC data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SPARC mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SPARC expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CCRCC, UCEC, and LUAD are the cancer types where SPARC mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.672	0.898	.003	32	view →
UCEC	DFS	Median	All	1.000	0.937	.025	4	view →
LUAD	DFS	Median	All	0.504	0.837	.029	2	view →
PDAC	OS	Quartile	All	0.296	0.567	.046	2	view →
GBM	DFS	Tertile	All	0.737	0.871	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SPARC–CCRCC (DFS)

Open the CCRCC breakdown →